Histone deacetylase inhibitor Helminthosporium carbonum (HC)-toxin suppresses the malignant phenotype of neuroblastoma cells

被引:43
作者
Deubzer, Hedwig E. [1 ,2 ]
Ehemann, Volker [3 ]
Westermann, Frank
Heinrich, Ralf [5 ]
Mechtersheimer, Gunhild
Kulozik, Andreas E. [2 ]
Schwab, Manfred [4 ]
Witt, Olaf [1 ,2 ]
机构
[1] German Canc Res Ctr, Clin Cooperat Unit Pediat Oncol G340, D-69120 Heidelberg, Germany
[2] Univ Heidelberg, Dept Pediat Oncol Hematol & Immunol, D-6900 Heidelberg, Germany
[3] Univ Heidelberg, Inst Pathol, Dept Gen Pathol Cytometry Facil, D-6900 Heidelberg, Germany
[4] German Canc Res Ctr, Dept Tumor Genet, D-6900 Heidelberg, Germany
[5] Univ Goettingen, Inst Zool, Dept Neurobiol, Gottingen, Germany
关键词
epigenetic therapy; cell cycle arrest; differentiation; E2F-1 regulated genes; RB tumor suppressor network;
D O I
10.1002/ijc.23295
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The survival rate of children with advanced neuroblastoma (NB) is dismal despite intensive multimodal therapy. The limited efficacy and the frequent and serious side effects of currently used therapeutic regimens necessitate the development of new, less toxic treatment strategies. This study shows that the histone deacetylase inhibitor Helminthosporium carbonum (HC)-toxin suppresses the malignant phenotype of both established NB cell lines and primary NB cells with and without amplified MYCN at dosages lower than 20 nM. HC-toxin induces cell cycle arrest and apoptosis as well as neuronal differentiation and diminishes both colony formation and invasive growth. These cellular changes are accompanied by the transcriptional repression of cell cycle regulators of the retinoblastoma (RB) tumor suppressor network found at high levels in NBs with poor prognosis, like E2F-1 and its targets Skp2, N-myc, Mad2 and survivin. The levels of the hypophosphorylated active form of RB, and of cyclin-dependent kinase inhibitors including P15(INK4b), p16(INK4a), p21(cip1/waf-1) and p27(kip1) are increased. In conclusion, nanomolar doses of the HDACI HC-toxin cause a shift to a differentiated and benign phenotype of NB cells that is associated with an activation of the RB tumor suppressor network. (c) 2007 Wiley-Liss, Inc.
引用
收藏
页码:1891 / 1900
页数:10
相关论文
共 43 条
[1]  
ALBINI A, 1987, CANCER RES, V47, P3239
[2]   Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? [J].
Baylin, SB ;
Ohm, JE .
NATURE REVIEWS CANCER, 2006, 6 (02) :107-116
[3]   Anticancer activities of histone deacetylase inhibitors [J].
Bolden, Jessica E. ;
Peart, Melissa J. ;
Johnstone, Ricky W. .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (09) :769-784
[4]   INHIBITION OF MAIZE HISTONE DEACETYLASES BY HC TOXIN, THE HOST-SELECTIVE TOXIN OF COCHLIOBOLUS-CARBONUM [J].
BROSCH, G ;
RAMSOM, R ;
LECHNER, T ;
WALTON, JD ;
LOIDL, P .
PLANT CELL, 1995, 7 (11) :1941-1950
[5]   Opinion - The role of apoptosis in cancer development and treatment response [J].
Brown, JM ;
Attardi, LD .
NATURE REVIEWS CANCER, 2005, 5 (03) :231-237
[6]   Antitumor activity of sodium valproate in cultures of human neuroblastoma cells [J].
Cinatl, J ;
Cinatl, J ;
Scholz, M ;
Driever, PH ;
Henrich, D ;
Kabickova, H ;
Vogel, JU ;
Doerr, HW ;
Kornhuber, B .
ANTI-CANCER DRUGS, 1996, 7 (07) :766-773
[7]  
Coffey DC, 2001, CANCER RES, V61, P3591
[8]  
DAHLSTRAND J, 1992, CANCER RES, V52, P5334
[9]   Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes [J].
De Preter, Katleen ;
Vandesompele, Jo ;
Heimann, Pierre ;
Yigit, Nurten ;
Beckman, Siv ;
Schramm, Alexander ;
Eggert, Angelika ;
Stallings, Raymond L. ;
Benoit, Yves ;
Renard, Marleen ;
De Paepe, Anne ;
Laureys, Genevieve ;
Pahlman, Sven ;
Speleman, Frank .
GENOME BIOLOGY, 2006, 7 (09)
[10]   MATRIX METALLOPROTEINASE-2 AND TISSUE INHIBITOR OF METALLOPROTEINASE-2 EXPRESSION IN PEDIATRIC TUMOR-CELLS - EFFECTS OF TUMOR-CELL PROLIFERATION MODULATORS ON GELATINOLYTIC ACTIVITY [J].
DEVEAS, RG ;
SCHWEIGERER, L ;
MEDINA, MA .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1995, 121 (05) :275-278